Maxion Therapeutics
Generated by Meeveem AI
"Creating antibody based drugs for previously untreatable ion channel and GPCR driven diseases."
Cambridge
•11 - 50 Employees
•Biotechnology
About Maxion Therapeutics
Maxion Therapeutics develops antibody based drugs for ion channel and GPCR driven diseases including chronic pain, autoimmunity and cardiovascular disease. Using its proprietary KnotBody® technology, the company creates first in class therapeutics with superior selectivity and potency. KnotBody® technology fuses naturally occurring miniproteins with antibodies to produce safe, efficacious and long acting drugs. The company addresses conditions affecting over 1.5 billion people worldwide where existing treatments suffer from poor efficacy. Its lead programme, MAX001, targets inflammatory diseases including atopic dermatitis and inflammatory bowel disease. Founded in 2020 in Cambridge, Maxion is advancing to clinical stage development.
30
Team Members
2020
Founded
Biotechnology
Sector
Hybrid
Work Environment
Our Vision
A world where ion channel and GPCR driven diseases such as chronic pain, autoimmunity and cardiovascular disease can be safely and effectively treated with selective, long acting therapies that transform patient outcomes.
Our Mission
Develops antibody based KnotBody drugs for ion channel and GPCR driven diseases, delivering transformational new therapeutic options for conditions with high unmet medical need.